Niagen Bioscience, Inc. (NAGE)
Data as of , from SEC Form 4 filings.
See up to 3 months of NAGE. The 7-day demo opens the 1M and 3M ranges and puts NAGE on your watchlist.
Start 7-day demoLatest NAGE insider trades
About Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. is an SEC registrant, filing under CIK 0001386570, classified as medicinal chemicals and botanical products. We track it alongside the rest of the Health Care sector.
NAGE Form 4 activity by transaction type, last 90 days
No Form 4 activity for NAGE in the last 90 days.
NAGE insider transactions (Form 4)
2319 Form 4 filings on record, the earliest from Oct 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carlos Luis Lopez - Officer | Grant or award | Common Stock | 2,314 | $2.71 | $6K | |
| Ozan Pamir - Officer | Grant or award | Common Stock | 4,255 | $2.71 | $12K | |
| Robert N. Fried - Officer | Grant or award | Common Stock | 1,106 | $2.71 | $3K | |
 Wing Tak Wendy Yu - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Wang Yu Gary Ng - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Ann Cohen - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Kristin Patrick - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Hamed Shahbazi - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Steven D. Rubin - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Frank L. Jaksch Jr. - Director | Grant or award | Stock Option (right to buy) | 31,746 | $0.00 | - | |
| Robert N. Fried - Officer | Option exercise | Stock Options (right to buy) | 20,000 | $0.00 | - | |
| Robert N. Fried - Officer | Option exercise | Common Stock | 20,000 | $2.61 footnote F1 | $52K | |
| ||||||
| Carlos Luis Lopez - Officer | Grant or award | Employee Stock Options (right to buy) | 41,420 | $0.00 | - | |
| Ozan Pamir - Officer | Grant or award | Employee Stock Options (right to buy) | 62,131 | $0.00 | - | |
| Robert N. Fried - Officer | Grant or award | Employee Stock Options (right to buy) | 503,937 | $0.00 | - | |
| Ozan Pamir - Officer | Open-market purchase | Common Stock | 2,220 | $6.85 | $15K | |
| Ozan Pamir - Officer | Open-market purchase | Common Stock | 4,465 | $6.81 footnote F1 | $30K | |
| ||||||
| Hamed Shahbazi - Director | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Frank L. Jaksch Jr. - Director | Option exercise | Common Stock | 50,001 | $3.66 | $183K | |
| Frank L. Jaksch Jr. - Director | Open-market sale | Common Stock | 37,161 | $6.19 | $230K | |
| Frank L. Jaksch Jr. - Director | Option exercise | Employee Stock Options (right to buy) | 50,001 | $0.00 | - | |
| Ozan Pamir - Officer | Open-market purchase | Common Stock | 2,907 | $7.36 | $21K | |
| Ozan Pamir - Officer | Grant or award | Employee Stock Options (right to buy) | 146,544 | $0.00 | - | |
NAGE insider trading FAQ
What is the latest insider trade for NAGE?
Niagen Bioscience, Inc. (NAGE) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-08. The full record for NAGE runs to 19 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NAGE stock?
No insider purchases of NAGE were filed in the last 90 days. 3 purchases are on record for this company.
How many insiders are selling NAGE stock?
No insider sales of NAGE were filed in the last 90 days. 1 sale is on record for this company.
Where can I see NAGE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NAGE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Carlos Luis Lopez view on EDGAR
- - Ozan Pamir view on EDGAR
- - Robert N. Fried view on EDGAR
- - Wing Tak Wendy Yu view on EDGAR
- - Wang Yu Gary Ng view on EDGAR
- - Ann Cohen view on EDGAR
- - Kristin Patrick view on EDGAR
- - Hamed Shahbazi view on EDGAR
- - Steven D. Rubin view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where NAGE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NAGE with a 7-day demo
- NAGE on your watchlist
- Every NAGE Form 4 filing on record
- Up to 3 months of NAGE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
